Literature DB >> 12787416

Renal cell carcinoma as a cause of end-stage renal disease in the United States: patient characteristics and survival.

Kevin P Stiles1, Michael J Moffatt, Lawrence Y Agodoa, S John Swanson, Kevin C Abbott.   

Abstract

BACKGROUND: The patient characteristics and mortality associated with renal cell carcinoma (RCC) as a cause of end-stage renal disease (ESRD) have not been characterized for a national population.
METHODS: An historical cohort study of renal cell carcinoma (RCC) was conducted from April 1, 1995, to December 31, 1999. Included were 360,651 patients in the United States Renal Data System (USRDS) who were initiated on ESRD therapy with valid causes of ESRD.
RESULTS: Of the study population, 1646 patients (0.5%) had RCC. The mean age of patients with RCC was 66.8 +/- 14.6 years versus 61.3 +/- 16.4 years for patients with other causes of ESRD (P < 0.01 by Student t test). The unadjusted 3-year survival (censored at the date of renal transplantation) of patients with RCC during the study period was 23% versus 36% in all other patients [adjusted hazard ratio (AHR), 1.10, 95% confidence interval (CI) 1.02-1.19, P = 0.019 by Cox regression]. However, patients with RCC who underwent nephrectomy (bilateral or unilateral) had significantly better survival compared to RCC patients who did not (AHR, 0.73, 95% CI, 0.63-0.85, P < 0.01), and their survival was not significantly different in comparison with nondiabetic ESRD patients. Bilateral nephrectomy (vs. unilateral) was not associated with any difference in adjusted mortality.
CONCLUSION: Among patients with ESRD, the demographics of those with RCC were similar to those of patients with RCC in the general population. Overall, patients with RCC had decreased survival compared to patients with other causes of ESRD; those who underwent nephrectomy had significantly better survival than those who did not, with survival comparable to patients with nondiabetic ESRD.

Entities:  

Mesh:

Year:  2003        PMID: 12787416     DOI: 10.1046/j.1523-1755.2003.00060.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Renal cell carcinoma arising from a horseshoe kidney in a chronic hemodialysis patient.

Authors:  Yasumasa Miyazaki; Akira Miyajima; Takahiro Maeda; Yujiro Ito; Nobuyuki Tanaka; Takeo Kosaka; Aya Masuda; Ryuichi Mizuno; Eiji Kikuchi; Ken Nakagawa; Mototsugu Oya
Journal:  Clin Exp Nephrol       Date:  2012-06-28       Impact factor: 2.801

2.  Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma.

Authors:  Hiroki Ishihara; Hironori Fukuda; Hidekazu Tachibana; Kazuhiko Yoshida; Hirohito Kobayashi; Toshio Takagi; Junpei Iizuka; Hideki Ishida; Yoji Nagashima; Tsunenori Kondo; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2021-02-27       Impact factor: 2.801

Review 3.  The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.

Authors:  Susie L Hu; Anthony Chang; Mark A Perazella; Mark D Okusa; Edgar A Jaimes; Robert H Weiss
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

4.  Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma.

Authors:  Samuel M Miller; Lauren E Wilson; Melissa A Greiner; Jessica E Pritchard; Tian Zhang; Deborah R Kaye; Harvey Jay Cohen; Robert D Becher; Linda L Maerz; Michaela A Dinan
Journal:  J Geriatr Oncol       Date:  2022-01-05       Impact factor: 3.929

5.  Trends and Outcomes with Kidney Failure from Antineoplastic Treatments and Urinary Tract Cancer in France.

Authors:  Imène Mansouri; Natalia Alencar de Pinho; Renaud Snanoudj; Christian Jacquelinet; Mathilde Lassalle; Clémence Béchade; Cécile Vigneau; Florent de Vathaire; Nadia Haddy; Bénédicte Stengel
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-06       Impact factor: 8.237

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.